SafeStitch Medical, Inc. Adds Sales Team Nationwide to Bring AMID Stapler® to Market
20 Abril 2012 - 3:33PM
Business Wire
SafeStitch Medical, Inc. (OTCBB: SFES) is bringing the AMID
Stapler® to market in the United States with the creation of a
nationwide sales team.
Dr. Philip Frost, largest beneficial
stockholder of SafeStitch Medical, Inc. (Photo: Business Wire)
The AMID Stapler was created to offer an innovative alternative
to manual suturing for inguinal hernia repair using the
Lichtenstein method. This hernia fixation device allows for mesh
manipulation, mesh fixation and skin closure with less retraction
force than required for manual suturing (based on cadaver data
study). The AMID Stapler’s design may help avoid the risk of
penetrating delicate vessels and nerves.
“We are ready to hit the ground running by bringing the AMID
Stapler into the operating rooms and allowing physicians to have
hands on experience with our device. Physicians spoke favorably
about the AMID Stapler at the International Hernia Congress,
specifically how easy it was to use, and I anticipate the product
will be well received and accepted. Already, we have appointments
to meet with numerous physicians who want to try out the product,”
said Jeffrey Spragens, President and CEO of SafeStitch Medical.
Comprised of thirty five direct sales managers, independent
representatives and distributors, SafeStitch’s sales team is
reaching all geographical areas that have high concentration of
hernia surgeries. The immediate goal is to create brand awareness
and adaptation among key opinion leaders and physicians by
demonstrating the AMID Stapler’s features and benefits over manual
suturing. SafeStitch’s new sales team will be led by JC Campbell,
Director of Sales of SafeStitch Medical since 2010.
Dr. Parviz Amid, one of the inventors of the AMID Stapler and
for whom the product is named, personally trained the sales team on
the Lichtenstein procedure using the AMID Stapler. “I was impressed
with the caliber of professionals I had the opportunity to train. I
am confident that with this training and the unique features of the
AMID Stapler, the Lichtenstein procedure will continue to advance
to the highest standards of patient care.”
The direct sales managers had the opportunity to meet Dr.
Phillip Frost during a training seminar at the corporate office in
Miami, Florida in March 2012. Dr. Frost, the largest beneficial
stockholder of SafeStitch Medical, reviewed the backgrounds of each
team member and offered them good wishes. “You could see the
excitement amongst the sales team. They are the forces behind the
AMID Stapler’s getting to market, and I believe that their skills
will produce the desired results.”
The sales team is currently taking orders for the AMID Stapler
and product is available for immediate shipment.
About SafeStitch Medical, Inc.
Miami, Florida-based SafeStitch Medical, Inc. is a publicly
traded medical device company focused on developing innovative
surgical devices with minimally invasive and endoscopic procedures
to deliver durable outcome for hernia repair, treatment of obesity
and other gastroespophageal disorders. Information about the
Company may be found on its website
at: www.safestitch.com.
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipate," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding our
product development and commercialization efforts, and our ability
to significantly improve clinical outcomes in patients, as well as
other non-historical statements about our expectations, beliefs or
intentions regarding our business, technologies and products,
financial condition, strategies or prospects. Many factors,
including those described herein and in our filings with the
Securities and Exchange Commission, could cause our actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements. These factors
include: whether we will be able to bring the AMID Stapler into
operating rooms to allow physicians to have a hands on experience
with the device; whether the AMID Stapler will be well received and
accepted; whether the AMID Stapler provides features and benefits
over manual suturing, and whether our sales force will be able to
demonstrate such features and benefits; whether we will be able to
gain appointments with physicians for the physicians to try the
AMID Stapler; whether the sales team will reach all geographical
areas that have high concentrations of hernia surgeries; whether we
will be able to create brand awareness and adaptation among key
opinion leaders; whether we have provided adequate training to our
sales representatives; whether the sales representative training
and the features of the AMID Stapler will advance the Lichtenstein
procedure to the highest standards of patient care; and whether the
AMID Stapler will be ready for shipments in April 2012. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements,
except as required under applicable law. We intend that all
forward-looking statements be subject to the safe-harbor provisions
of the PSLRA.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50247396&lang=en
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024